Addex to Attend BIO-Europe Conference in Hamburg

Geneva, Switzerland, November 8, 2019 – Addex Therapeutics (SIX: ADXN), a leading allosteric modulation-based drug discovery and development company, today announced that Chief Executive Officer Tim Dyer will provide a corporate update during a presentation at  the 25^th Annual BIO-Europe International Partnering Conference, Hamburg, Germany, November 11 – 13, 2019.
Mr. Dyer and Dr. Robert Lütjens, Head of Discovery – Biology, will be available for one-on-one meetings with attendees at the conference.
Disclaimer / Forward-looking statements: This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. This document does not constitute a prospectus according to art. 652a or art. 1156 of the Swiss Code of obligations or art. 27 et seq. of the Swiss Exchange Listing Rules. This publication may contain certain forward-looking statements concerning the Company and its business, including with respect to the potential listing of the Company’s securities in the United States. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements; the listing of the Company’s securities in the United States remains subject to approval by regulatory authorities. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.